Tags : Neutralizing

Biotech COVID-19

AstraZeneca Plans to Advance the Combination of Neutralizing Antibody for

Shots: AstraZeneca has licensed Vanderbilt University’s coronavirus-neutralizing Abs & plans to advance a pair of these mAbs into clinical development as a combination therapy for COVID-19. The agreement follows AstraZeneca and Vanderbilt collaboration in Apr’20 AstraZeneca has evaluated the ability of 1,500+ mAbs to bind to the SARS-CoV-2 virus and inhibit its capacity to infect […]Read More

Biotech COVID-19

AstraZeneca Focuses on the Discovery of Monoclonal Antibodies Neutralizing SARS-CoV-2

Shots: AstraZeneca highlighted its efforts towards the development of Ab against the pandemic SARS-CoV-2 virus by deploying its internal expertise and via news collaboration with government and academia The Chinese Academy of Sciences and Vanderbilt University Medical Center are providing AstraZeneca with genetic sequences for Ab, discovered against SARS2-CoV-2 for further in silico and in […]Read More